NEW DELHI: India has been reporting one of the lowest Covid-19 death rates in the world, and the figure has declined further to 1.76 percent compared to a global average of 3.3 percent, said the Wednesday the Union Ministry of Health.
He also said that Covid-19 deaths per million people in India is one of the lowest in the world.
“While the world average is 110 deaths per million inhabitants, India reports 48 deaths per million inhabitants. The comparative figure for Brazil and the United Kingdom is 12 and 13 times higher, respectively,” the ministry said.
India’s Covid-19 case count surpassed 37 lakh on Wednesday with 78,357 new cases of the disease reported in one day, while the number of recoveries exceeded 29 lakh, bringing the recovery rate to 76.98 percent, showed data from the Union Ministry of Health.
The death toll rose to 66,333 and 1,045 more deaths were reported in 24 hours. India has so far reported 37,69,523 cases of the viral disease, according to data updated at 8 am.
As part of the Covid-19 management and response policy, the Center’s clear focus has not only been to contain the coronavirus-related fatality, but also to reduce deaths by providing quality clinical care to critically ill and critically ill patients, he said .
Collaborative efforts by the Center, the states and the union territories have resulted in the strengthening of health facilities across the country, the ministry said.
Up to 1,578 hospitals dedicated to Covid provide quality healthcare. The central government has also issued the standard of care guidelines incorporated into the Clinical Treatment Protocol.
AIIMS, New Delhi, has been conducting e-ICU sessions to develop the capabilities of ICU physicians in the clinical management of critically ill patients to reduce fatality. Experts in knowledge and proficiency have been conducting twice-weekly tele or video consultation sessions since July 8 for physicians attending ICUs in state hospitals.
To date, 17 teleshoots have been held and 204 institutions have participated in them, the ministry reported.
To further develop the ICU, clinicians’ clinical management capabilities for the treatment of critically ill patients, AIIMS, New Delhi, in collaboration with the Ministry of Health, has developed frequently asked questions (FAQ).
One of them clarifies that Remdesivir and tocilizumab are experimental therapies and should not be used as empirical therapy for suspected cases. They should be used only in patients with proven Covid-19, where clinically indicated, the ministry said, stressing that there is no evidence to support the use of these two drugs in asymptomatic patients with comorbidities.
In one of the responses, the ministry said, tocilizumab is an experimental therapy, has a limited role and should be used only in patients with cytokine syndrome after ruling out active infections.
Regarding the role of favipiravir, the ministry said that studies have used this drug mainly in mild or asymptomatic Covid-19 cases, stating that it prevents progression, while the majority of this cohort recover only with supportive care and follow-up and generally does not require specific therapy.
The evidence is weak for the use of favipiravir and it is not currently recommended in national guidelines, he said.
According to the FAQ, depression is a common finding in Covid patients that can be due to a number of reasons including being in isolation, anxiety related to the disease, social stigma, among others. Such patients need empathy and psychological counseling, preferably from a trained healthcare worker such as a psychologist / psychiatrist, he said.
The ministry said sudden deaths have been reported both on presentation to the emergency department and at the hospital. Reasons that have been proposed include a sudden cardiac event / ACS, preceding a silent hypoxia that went unnoticed, or due to a thrombotic complication such as pulmonary thromboembolism.
“Patients with risk factors for developing severe Covid-19 or with previous comorbid conditions, such as coronary heart disease or chronic lung disease, should be strictly monitored for saturation. They should not be allowed to move around unsupervised. They should be used. anticoagulant in all patients at risk who do not have any risk factor for bleeding, “explained the ministry.
In regards to the role of plasma therapy, the FAQ said that convalescent plasma collected from ABO compatible donors with high neutralization titers can be administered to patients at risk of developing severe Covid in the early stages of the disease. However, it should also be considered an experimental therapy and should be used with caution, he said.
He also said that Covid-19 deaths per million people in India is one of the lowest in the world.
“While the world average is 110 deaths per million inhabitants, India reports 48 deaths per million inhabitants. The comparative figure for Brazil and the United Kingdom is 12 and 13 times higher, respectively,” the ministry said.
India’s Covid-19 case count surpassed 37 lakh on Wednesday with 78,357 new cases of the disease reported in one day, while the number of recoveries exceeded 29 lakh, bringing the recovery rate to 76.98 percent, showed data from the Union Ministry of Health.
The death toll rose to 66,333 and 1,045 more deaths were reported in 24 hours. India has so far reported 37,69,523 cases of the viral disease, according to data updated at 8 am.
As part of the Covid-19 management and response policy, the Center’s clear focus has not only been to contain the coronavirus-related fatality, but also to reduce deaths by providing quality clinical care to critically ill and critically ill patients, he said .
Collaborative efforts by the Center, the states and the union territories have resulted in the strengthening of health facilities across the country, the ministry said.
Up to 1,578 hospitals dedicated to Covid provide quality healthcare. The central government has also issued the standard of care guidelines incorporated into the Clinical Treatment Protocol.
AIIMS, New Delhi, has been conducting e-ICU sessions to develop the capabilities of ICU physicians in the clinical management of critically ill patients to reduce fatality. Experts in knowledge and proficiency have been conducting twice-weekly tele or video consultation sessions since July 8 for physicians attending ICUs in state hospitals.
To date, 17 teleshoots have been held and 204 institutions have participated in them, the ministry reported.
To further develop the ICU, clinicians’ clinical management capabilities for the treatment of critically ill patients, AIIMS, New Delhi, in collaboration with the Ministry of Health, has developed frequently asked questions (FAQ).
One of them clarifies that Remdesivir and tocilizumab are experimental therapies and should not be used as empirical therapy for suspected cases. They should be used only in patients with proven Covid-19, where clinically indicated, the ministry said, stressing that there is no evidence to support the use of these two drugs in asymptomatic patients with comorbidities.
In one of the responses, the ministry said, tocilizumab is an experimental therapy, has a limited role and should be used only in patients with cytokine syndrome after ruling out active infections.
Regarding the role of favipiravir, the ministry said that studies have used this drug mainly in mild or asymptomatic Covid-19 cases, stating that it prevents progression, while the majority of this cohort recover only with supportive care and follow-up and generally does not require specific therapy.
The evidence is weak for the use of favipiravir and it is not currently recommended in national guidelines, he said.
According to the FAQ, depression is a common finding in Covid patients that can be due to a number of reasons including being in isolation, anxiety related to the disease, social stigma, among others. Such patients need empathy and psychological counseling, preferably from a trained healthcare worker such as a psychologist / psychiatrist, he said.
The ministry said sudden deaths have been reported both on presentation to the emergency department and at the hospital. Reasons that have been proposed include a sudden cardiac event / ACS, preceding a silent hypoxia that went unnoticed, or due to a thrombotic complication such as pulmonary thromboembolism.
“Patients with risk factors for developing severe Covid-19 or with previous comorbid conditions, such as coronary heart disease or chronic lung disease, should be strictly monitored for saturation. They should not be allowed to move around unsupervised. They should be used. anticoagulant in all patients at risk who do not have any risk factor for bleeding, “explained the ministry.
In regards to the role of plasma therapy, the FAQ said that convalescent plasma collected from ABO compatible donors with high neutralization titers can be administered to patients at risk of developing severe Covid in the early stages of the disease. However, it should also be considered an experimental therapy and should be used with caution, he said.
.
